These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 30127394)

  • 1. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
    Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
    Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
    Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
    Hassel JC; Heinzerling L; Aberle J; Bähr O; Eigentler TK; Grimm MO; Grünwald V; Leipe J; Reinmuth N; Tietze JK; Trojan J; Zimmer L; Gutzmer R
    Cancer Treat Rev; 2017 Jun; 57():36-49. PubMed ID: 28550712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
    Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.
    Milberg O; Gong C; Jafarnejad M; Bartelink IH; Wang B; Vicini P; Narwal R; Roskos L; Popel AS
    Sci Rep; 2019 Aug; 9(1):11286. PubMed ID: 31375756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.
    Zeng H; Jiang Q; Zhang R; Zhuang Z; Wu J; Li Y; Fang Y
    Sci Rep; 2024 Oct; 14(1):22872. PubMed ID: 39358546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
    Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
    J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
    Champiat S; Lambotte O; Barreau E; Belkhir R; Berdelou A; Carbonnel F; Cauquil C; Chanson P; Collins M; Durrbach A; Ederhy S; Feuillet S; François H; Lazarovici J; Le Pavec J; De Martin E; Mateus C; Michot JM; Samuel D; Soria JC; Robert C; Eggermont A; Marabelle A
    Ann Oncol; 2016 Apr; 27(4):559-74. PubMed ID: 26715621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indicators of responsiveness to immune checkpoint inhibitors.
    Shields BD; Mahmoud F; Taylor EM; Byrum SD; Sengupta D; Koss B; Baldini G; Ransom S; Cline K; Mackintosh SG; Edmondson RD; Shalin S; Tackett AJ
    Sci Rep; 2017 Apr; 7(1):807. PubMed ID: 28400597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
    Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
    Ann Oncol; 2017 Jul; 28(7):1672-1673. PubMed ID: 28407116
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ; Ott PA
    Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A; Larkin J
    Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade.
    Naidoo J; Page DB; Wolchok JD
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.